Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I've been trying to understand what the controversy
is all about. I knew there was a controversy, but
I didn't know the specifics.
This article explains the point of view for the side trying to stop human embryo usage. It's a well written article, frank, easy to understand.
This is the essential paragraph. It's talking about an 8 cell human embryo.
LOL, Using Charts to Forecast The Future
Charts are useless for predicting the future.
This statement is always true.
But, it can be added that charts are nevertheless useful.
Charts are useful for looking at what has already
happened.
And looking at a Weekly, 9 month chart of OCAT,
is the most useful of all. The daily chart is cluttered
and useless.
Looking at this chart you will see 3 KEY Events that
render everything before them, irrelevant.
The first Key Event was the reverse split. The
reverse split reconfigured the share structure.
If you zoom out, (weekly scale), you can easily
spot the erratic trading before the reverse split,
compared to after.
So, the reverse split, effectively renders the chart
irrelevant, beforehand. The stock trades differently
now, period.
The next Key Event was the Lancet data release.
This spike last October renders the fundamental
picture irrelevant before it. It represents key
scientific success, primarily in product safety.
The next Key Event was the NSDQ Up List.
This again renders everything before it, irrelevant.
Trading will now change characteristics again,
because the NSDQ, ain't no OTCBB !
Nothing before the February Up List is relevant.
This rendering irrelevant by Key Events,
will happen again and again.
There's a nice little spike at each Key Event,
how handy.
And this is where we find ourself now.
EVERYTHING before the February Up List is
irrelevant.
We're 5 weeks up in a row, in the relevant period.
And that ain't nothing.
Does the chart tell us anything about the future?
NO.
The CEO could wake up in a hotel room with
the JV cheerleader squad. And it'd be game
over for him and the company for a little while.
Cathy could wake up with a giant fly-eye.
And that would be game over forever.
The chart is no help here, is it?
But the chart is handy for a look back.
This stuff below does help with the future.
But you have to understand it.
And that's up to you.
I hear that train a comin ...
We can, ... take the stem cells and turn them into essentially brand new, young, juvenile retinal pigment epithelium and give somebody a fresh layer of these cells ... if they have macular degeneration
Dr. Stephen Schwartz, UCLA and Jules Stein Institute
Charlie Rose show, 4/22/14
http://www.charlierose.com/watch/60378567
"There are ... dozens of retinal degenerative diseases
... caused by the loss of the RPE cells."
-Dr. Robert Lanza
Dr. Lanza
ONVOs Not On Any Top Gainers Lists
It seems like it should be.
This Week, And Next
Company---------Market Cap
Johnson & Johnson (NYSE: JNJ ) $279 billion
Novartis $240.8 billion
Pfizer (NYSE: PFE ) $211.6 billion
Merck (NYSE: MRK ) $163.9 billion
Novo Nordisk $143.3 billion
Sanofi $130.7 billion
GlaxoSmithKline (NYSE: GSK ) $113.1 billion
Bristol-Myers Squibb $108.5 billion
Are you talkin to me?
No, they're all talking to ONVO!
What If There's an 8K Every Day For_a_Week?
How many companies does the 80% success rate add
up to?
We need to push the share price up
to the capitulation point for the shorts.
The day this happens may not be too far off.
Let's hope there is more news coming of the
deals, and it is presented in the worse possible
way for the shorts.
The Short's Decision Cycle is_about_to_be Interrupted
or let's watch and see.
Unexpected early release of good news, Hmmm?
Now we have to ponder, good word, how much
profits will increase each quarter.
Profits, any profits, are good.
We're in The Longest Uptrend Since The ReverseSplit!
last August, 2014
Look at the weekly chart, if you want to follow along.
We've just had 4 weeks of upward action.
And the share price is trading above
the 20 and 50 moving averages.
So, this is a slight positive.
Remember, we've only been on the NSDQ for
9 weeks !
I look at something like this 4 week run as akin
to building a rather large bon fire. For 4 weeks,
now 5, the dry wood has been gathered and
carefully piled to burn evenly and maintain good
air flow when burning.
If we get a positive announcement or something
emerges from somewhere, it will be like a spark
that sets things ablaze, and the share price
will takeoff.
We can also get a down pour, and have to start
again.
The reverse split begat the NSDQ which has now
lead us to the Funds beginning to buy after only
9 weeks !!!
It's important to put the funds issue into proper
perspective, and point out the essential item
of importance of the Funds.
The essential item of importance is that the funds
have discovered OCAT in the first place.
And secondly, it's good to know, the funds follow
each other. When one buys, others buy. So, it's
a beginning.
So, an uptrend has begun, now let's see if it lasts!
If the share price blows through the 200 day
moving average at 8.35, that'll be a breakout!
OCAT hasn't traded above the 200 day, since 2011.
(weekly chart)
The latest news from the European EMA,
is ALSO positive, VERY POSITIVE.
http://www.clinicaspace.com/News/ocata-therapeutics-receives-regulatory-guidance/369015
Sooner or later, the share price will move to reward
the good news that continues to flow.
The FDA will probably act before too long.
And I expect that will be positive news as well.
Increment, by increment Ocata continues to make
progress.
So, this uptrend has no magnitude, it's a 1 point move,
but it's still the most sustained move since last August.
And it's interesting because it's AFTER, the NSDQ
up list. It's the first emerging technical event after
the nasdaq up list. So, we'll see.
We can, ... take the stem cells and turn them into essentially brand new, young, juvenile retinal pigment epithelium and give somebody a fresh layer of these cells ... if they have macular degeneration
Dr. Stephen Schwartz, UCLA and Jules Stein Institute
Charlie Rose show, 4/22/14
http://www.charlierose.com/watch/60378567
"There are ... dozens of retinal degenerative diseases and these diseases are ... caused by the loss of the RPE cells."
-Dr. Robert Lanza
Dr. Lanza
WE ALREADY HAVE PHASE 2 DATA.
That's what phase 1|2 means!!!
It's NOT Phase one-half.
It's a complete phase 1 trial,
AND a PARTIAL phase 2 !!!
Thus, Phase 1|2 !!!
We have some confirmation from phase 2,
it's just being ignored.
Confirmation of EFFICACY, IT WORKS !!!
And this will not always be so.
I don't see why dry-AMD cannot be
pivotal status. There is absolutely no
treatment for 1.8 MILLION cases each year!!!
Talk about an UN-MET NEED !!!
What If The Unreported Patients Have 20/10 Vision?
That is to say, what if what we don't know is
better than we imagined?
We already know that the RPE Technology
essentially re-manufactures the bottom layer
of the retina, restoring those kinds of blindness.
What if this actually re-engineers the eye,
to make it see better than originally?
What would that be worth?
I'd say a lot!
We can, ..., take the stem cells and turn them into essentially brand new, young, juvenile retinal pigment epithelium and give somebody a fresh layer of these cells that could take them, if they have macular degeneration and say they're 40, 50, 70 years old, for the duration.
(for the duration means for the rest of their life)
Dr. Stephen Schwartz, UCLA and Jules Stein Institute
Charlie Rose show, 4/22/14
http://www.charlierose.com/watch/60378567
"There are ... dozens of retinal degenerative diseases and these diseases are ... caused by the loss of the RPE cells."
-Dr. Robert Lanza
Dr. Lanza
Big Pharma is Big Vacuum Tube, And_They're_Toast!!!
The Laboratory 8 Cell Human Embryo is the Future
of Medicine.
And Ocata is FIRST!!!
The vacuum tube lobby couldn't stop the integrated
circuit from being developed in the 1960's.
And Big Pharma won't stop cell therapies now.
It's all the same. It's the progression of
technology.
It cannot be stopped.
Ocata is FIRST!!!
We Get First Quarter 10Q in 3 Weeks
If there are small profits, as expected, and
information about orders, the share price
will quickly snap back and then
begin to rise dramatically.
The shorts have over played their hand here.
Even 4.50 brought good buying today,
3.29 was absurd, and brought massive buying.
Buy, Sell, or Hold. Those are your only choices.
Someone is Accumulating Big Blocks of OCAT Shares
Look at a 10 day chart, last week someone came
in above the market price and and bought EVERYTHING
the last few days of last week. It happened again
on monday.
They're taking a few days off, but they'll probably
be back. We'll see.
The price level has risen slightly to the 7 area.
Ocata has the first embryonic stem cell derived
therapy to pass FDA phase 1|2 trials.
It's the FIRST regenerative therapy of any kind.
These RPE tissue transplants REBUILD the retina.
The RPE therapy cures many type of blindness.
"There are ... dozens of retinal degenerative diseases and these diseases are ... caused by the loss of the RPE cells."
-Dr. Robert Lanza
Dr. Lanza
Safety, Well Tollerated, and Efficatious!
What's not to like?
Two Moons---kaChing!!!
The phase 1|2 initial injection, run up took
the share price to $28.
That would push the market cap to nearly
the Billion mark.
I think this will happen later this year.
Two Moons---kaChing!!! Indeed.
Hey Rally, you're right. Bravo for you!
I hope you find somebody to fight with,
it's not gonna be me.
I sold a third of my position at $7,
this helped my anxiety a bit,
from the disastrous 2014,
I bought it back in the high $3s.
I think the $3.29 low is a washout low,
and the direction now is up, for quite
a while.
Profits are coming, this quarter and next.
My thinking on the huge 19 million short
position, is that it's irrelevant, but nice
to know.
The price for a stock is determined each day.
Don't talk to me again.
What Have the Shorts Taught Us?
What we have learned is when ONVO gets into
the 3s and 4s, massive buying comes in and
overwhelms all other factors.
I bought my shares back in the high 3s,
thank you shorts !
I improved my average price, but only slightly, sigh!!!
Hope everyone improved their ave price.
I think we'll see indications of profits in the next 10Q,
first week of May...it's only a few weeks away.
Wonder if another Short Will Get anotherMarginCall?
I've never witnessed a mother of all short covering
rally. Somehow that just sounds like a party!
I've seen this sort of thing trading commodities.
But this was in the days of open outcry trading pits,
and slips of paper order tickets, you know, the old days,
the nineties!!
Yesterday's EOD event might have been a mini-bear trap
that ended rather quickly. Because I think it's over.
But we may see these mini-bear traps 'all the way up'.
We'll see, I guess.
High of the day, that's gotta be making the day trader
shorts sweat!
Phase1|2 First Injection Run Was To $28!!!
The first Phase 2 AMD injection will bring
great excitement, great and genuine!
Ocata is the first to develop,
the first thru the FDA,
and will be the first to market!
And don't forget about Cowboy and Cathy.
link-google it yourself, it's all there
Ocata is the first regenerative therapy
for ophthalmology.
Maybe the first regenerative therapy period!
The chart is looking awfully strong for "no news" !!!
7s and it's only Tuesday!
Get Eddy to supervise the the first injection.
Let's Light This Candle !!!
I Think a Bear Trap Has Occurred!
Look backwards from the 3.29 low, on 30 mar
it seemed to go down almost everyday for a
month.
This corresponds to the 3/13 to 3/31 period,
when about 3 million more short positions
were added.
But the 30th was the day of the low,
and the period ended on the 31st.
The following 9 days we recovered almost
2 full dollars, depending on what number
you use for yesterday's high.
So, so far, it's rising faster than it went down!
This is exciting.
I think yesterday's, EOD activity, was a margin call,
and a forced close out of a short position.
If the shorts are burning through their margin,
and are getting margin calls, we will see these up spikes
again and again.
In the old days you would look for volume for confirmation.
But I think the algorithms mask, or distribute the volume
making volume a much less reliable indicator.
We'll see.
OK, there's the Short Data for 3/31
3/31/2015 19,348,070
3/13/2015 16,573,655
Read more: http://www.nasdaq.com/symbol/onvo/short-interest
WOW, that's quite an increase, in shorts!
This rise must be some sort of bull trap.
But it looks like a (genuine)bull run, to me.
Maybe the shorts are wrong, or becoming wrong.
(This data is usually a day late. They publish a schedule
but I guess they don't care about following it or fixing
the future schedules, wtf?, whatever)
No Short Data at This Link
http://www.nasdaq.com/symbol/onvo/short-interest
3/31/15 data should have been posted 10 Apr 2015 after 4pm
Nasdaq Short Data is over due
The Short Data for 3/31/15 was scheduled for
dissemination on 4/10/15 after 4pm.
This data is usually out the following day.
I've never actually seen in on the day scheduled
after 4pm, it's alway late.
If there's a big lessening of the 16 plus million short
position, maybe that caused a spike.
You can track this data from daily reports, but you
have to parse through a huge data file.
LOL What?Huh?_30Days_Later WE_WILL_KNOW
one month[30 Days] after treatment, his vision had improved 10 lines, which is 20/40
This is why I think phase 2 isn't going to take very long.
Sure they'll keep watching the patients, but
they will be watching people with fresh healthy eyes.
"We treated a 75-year-old horse rancher whose vision was 20/400, which is legally blind, and one month[30 Days] after treatment, his vision had improved 10 lines, which is 20/40 -- and he can even ride his horses again. Other patients report similarly dramatic improvements. It's made a huge difference in the quality of their life," Lanza added
Phase 2---Patient 1, One Month, 30 Days! RESULTS! or a good indication!
Phase 2---Patient 1, One Month, 30 Days! RESULTS! or a good indication!
Phase 2---Patient 1, One Month, 30 Days! RESULTS! or a good indication!
If Ocata injects all 20 within a week or Two,
this will drive the market to frenzy,
absolute frenzy!!!
Let us break down the above paragraph:
We treated a 75-year-old horse rancher whose vision was 20/400...
and one month after...
his vision was 20/40
Other patients report similarly dramatic improvements.
(other---means more than only cowboy)
Ocata is ONE eyeball injection.
Eylea is eyeball injections for LIFE!!!
Cowboy 20/40 is REAL !
The RPE Therapy is REAL !
The hard science is DONE.
The only obstacle left is the FDA.
And they're ONBOARD !
ONE INJECTION, ONE, and we are officially in FDA phase 2 trials.
And 30 days later we will know.
Phase 2 will tell us if the 75 year old rancher was a lucky one shot,
or if the RPE therapy works for everyone with a repairable retina.
We'll see.
I think the evidence already warrants optimism,
if not exuberance.
From the CC 12Mar2015
PW_CC_12mar15(edited)
Our number one corporate objective for 2015 is the initiation of the next phase of our clinical trials.
We plan to initiate our Phase II trial for dry AMD in the second quarter of this[2015] year.
This Phase II study will include up to three cohorts of approximately 20 patients each.
We intend to complete the first cohort dosing during 2015.
Each of the three cohorts will be treated with a different immune suppression regimen to determine how much, if any, immune suppression is required.
PW_CC_12mar15(end)
I bet they'll find ONE patient to inject in Q2, and get the ball rolling.
Find a 20/80 guy, and BAM!,
a month later he's 20/20, BAM !
That's all it would take to light this candle.
Let's Light This Candle !
http://www.sciencetimes.com/articles/812/20141016/stem-cell-technology-macular-degeneration-visual-problems.htm
Stem Cells provide long-term treatment for the almost blind
Alfer A. Guiang Oct 16, 2014 09:32 AM EDT
In recent years, the wonder of stem cells has been subject of discussions in the academe and the medical world with the discovery on stem cells' efficacy in certain illnesses, including the recent findings on type 1 Diabetes.
Earlier this week, another breakthrough discovery circulated in most media venues, and this still involves stem cell transplants for the treatment of forms of macular degeneration which is said to be a leading cause of loss of vision.
The study was funded by U.S.-based company called Advanced Cell Technology[now Ocata] and was published on The Lancet on October 15 (Wednesday).
The research involved 18[now 38] people who received the transplants to treat forms of severe vision loss resulting from two types of macular degeneration.
New Video, KM does a great job.
http://video.cnbc.com/gallery/?video=3000369834
(not sure of when this video took place)
I think good things will come with each new quarterly
report.
Inject_A_Phase2 Patient, And_30Days_Later WE_WILL_KNOW
"We treated a 75-year-old horse rancher whose vision was 20/400, which is legally blind, and one month after treatment, his vision had improved 10 lines, which is 20/40 -- and he can even ride his horses again. Other patients report similarly dramatic improvements. It's made a huge difference in the quality of their life," Lanza added as he explained the wonders stem cell transplant could do to the living species body.
Cowboy 20/40 is REAL !
The RPE Therapy is REAL !
The hard science is DONE.
The only obstacle left is the FDA. And they're are ONBOARD !
ONE INJECTION, ONE, and we are officially in FDA phase 2 trials.
From the CC 12Mar2015
PW_CC_12mar15(edited)
Our number one corporate objective for 2015 is the initiation of the next phase of our clinical trials.
We plan to initiate our Phase II trial for dry AMD in the second quarter of this[2015] year.
This Phase II study will include up to three cohorts of approximately 20 patients each.
We intend to complete the first cohort dosing during 2015.
Each of the three cohorts will be treated with a different immune suppression regimen to determine how much, if any, immune suppression is required.
PW_CC_12mar15(end)
I cannot fathom that they couldn't find ONE patient to inject in Q2, and get the ball rolling.
Find a 20/80 guy, and BAM, a month later he's 20/20, BAM !
That's all it would take to light this candle.
http://www.sciencetimes.com/articles/812/20141016/stem-cell-technology-macular-degeneration-visual-problems.htm
Stem Cells provide long-term treatment for the almost blind
Alfer A. Guiang Oct 16, 2014 09:32 AM EDT
In recent years, the wonder of stem cells has been subject of discussions in the academe and the medical world with the discovery on stem cells' efficacy in certain illnesses, including the recent findings on type 1 Diabetes.
Earlier this week, another breakthrough discovery circulated in most media venues, and this still involves stem cell transplants for the treatment of forms of macular degeneration which is said to be a leading cause of loss of vision.
The study was funded by U.S.-based company called Advanced Cell Technology and was published on The Lancet on October 15 (Wednesday).
The research involved 18 people who received the transplants to treat forms of severe vision loss resulting from two types of macular degeneration.
Nine had Stargardt macular degeneration, the leading cause of juvenile blindness, while nine had dry atrophic age-related macular degeneration, the most common cause of vision loss in people over 50, reports from CNN said.
The participants were observed and followed for three years, and all of them showed no signs of rejection of the cells and no abnormal growth, tumor formation or unwanted tissue types in any of the patients during that time period, CNN reported.
On average, the vision of the patients improved about three lines on the standard eye chart. Overall, 10 of the 18 patients said they had significant improvements in their vision, especially on those parts that received stem cells.
Patients in a control group who were not part of the stem cell transplant did not show similar sight improvement.
According to Dr. Robert Lanza, chief scientific officer at Advanced Cell Technology and funder of the study, said in a journal news release, "Embryonic stem cells have the potential to become any cell type in the body, but transplantation has been complicated by problems. Those problems include the rejection of the transplanted cells by the patient's immune system, as well as the danger that the cells might spur certain types of cancers called teratomas."
"This is the first report showing that the cells are safe in the long term and that they can actually help people," Lanza said,
"You can turn these into insulin-producing cells for diabetes, heart cells to treat heart disease. They can be turned into nerve cells to treat Alzheimer's disease or Parkinson's disease or stroke," he elaborated.
"We treated a 75-year-old horse rancher whose vision was 20/400, which is legally blind, and one month after treatment, his vision had improved 10 lines, which is 20/40 -- and he can even ride his horses again. Other patients report similarly dramatic improvements. It's made a huge difference in the quality of their life," Lanza added as he explained the wonders stem cell transplant could do to the living species body.
"These cells can be used to treat a wide range of human diseases caused by tissue loss or dysfunction," he added as he was optimistic that these groundbreaking findings in stem cell research are just the beginning.
Meanwhile, Dr. C. Michael Samson, co-director of Ocular Immunology and Uveitus Service at The New York Eye and Ear Infirmary of Mount Sinai, New York City is hopeful that stem cell technology would eventually be the treat vision loss in patients with retinal disease.
"Vision loss from damage to the retina, whether from macular degeneration or diabetes, is irreversible with currently available treatment options. Stem cell technology offers such patients the best hope in recovering lost vision," he said.
"This pilot study suggests that progress is being made in making stem cell technology to recover vision a reality," Dr. Samson added.
http://www.sciencetimes.com/articles/812/20141016/stem-cell-technology-macular-degeneration-visual-problems.htm
brand new, young, juvenile...This Sounds So Sexy!
If you got balls !, eyeballs that is, Ocata can fix'em !!!
They can put a fresh layer on your balls, your eyeballs !
We can, ..., take the stem cells and turn them into essentially brand new, young, juvenile retinal pigment epithelium and give somebody a fresh layer of these cells that could take them, if they have macular degeneration and say they're 40, 50, 70 years old, for the duration.
(for the duration means for the rest of their life)
Dr. Stephen Schwartz, UCLA and Jules Stein Institute
Charlie Rose show, 4/22/14
http://www.charlierose.com/watch/60378567
This is a curative therapy, a regenerative therapy,
the first stem cell derived therapy to pass FDA phase
1/2 trials.
This is righteously brand new, young, and juvenile !!!
And the chart is beginning to reflect something very, very,
powerful happening.
Look at the moving averages, they are coming together
in the 6-something range in a very unusual way that
looks like tremendous power is building for a monumental
move of some kind?
I've been doing this a while, and I've never seen
anything like this before. There's a larger 5 year plus
base that has built up. And a more recent base after
the reverse split run up and pull back.
This most recent base is what interests me.
It looks unusually singular. It looks like focused energy
of some sort.
I think this stock is ready for lift off.
It's slowly exiting the 6's, might see 7’s next week,
or maybe this afternoon.
I_Guess_The_Market Doesn't Really Care about Deals_Either
L’Oreal Teams with Organovo to 3D Print Skin Tissue
April 2015
Just after announcing the successful 3D printing of kidney cells, bioprinting firm Organovo has decided to add 3D printed skin to its portfolio of printable organ tissues. The company has signed a Research Collaboration Agreement with L’Oreal USA Products, Inc to 3D print skin models using their NovoGen Bioprinting Platform.
While the agreement gives L’Oreal exclusive rights to the models for use in the R&D and production of its own non-prescription beauty and skin care products, Organovo can still sell its skin tissues for use in pharmaceutical testing, therapy, and surgical transplants. The partnership will undergo three different phases: the initial development of the 3D printed skin tissue models, followed by validation, followed by commercial supply. Each step is contingent on L’Oreal’s decision of whether or not to move onto the next phase, as determined based on a set of performance criteria.
At every point along the way, L’Oreal will hand over its cash in the form of upfront payments and payments for deliverables from Organovo. Though the companies will negotiate a deal regarding Organovo’s exclusive commercial supply of the tissue models, tied to standard licensing and royalty agreements, no specific commercial terms have yet been disclosed.
brand new, young, juvenile retinal pigment epithelium RPE
We can, ..., take the stem cells and turn them into essentially brand new, young, juvenile retinal pigment epithelium and give somebody a fresh layer of these cells that could take them, if they have macular degeneration and say they're 40, 50, 70 years old, for the duration.
(for the duration means for the rest of their life)
Dr. Stephen Schwartz, UCLA and Jules Stein Institute
Charlie Rose show, 4/22/14
http://www.charlierose.com/watch/60378567
How long can the market ignore this success?
The market can pour 400 million dollars into Go Daddy,
a failed web site company,
but,
it has no love for a curative therapy for blindness?
"There are ... dozens of retinal degenerative diseases and these diseases are ... caused by the loss of the RPE cells."
-Dr. Robert Lanza
Dr. Lanza
Up_10%_Today, We'll_Be_Fine, If_it_Does_This_Everyday
for a while.
Now, if it doubles, we'll be fine. LOL
But of Course, Ocata is at Bankruptcy's DoorstepROTFLOL
Two Moons KA-CHING !!!
I've come to thinking that there is no 'reason'
for any single day's action in a share's price.
But look back at a 5 year chart, and the number
6 jumps out as a sort of baseline price for Ocata.
And that's what has happened. A gigantic base
has been built it this stock. The old rule of thumb
applies here: The greater the base, the higher
the race.
When this stock takes off you can take that base
on the chart and turn it vertical 90 degrees to
get an idea how high Ocata's share price will go.
These charts are logarithmic.
The first milestones for the share price are
the 8.39 and 12.73 tops. After it blows through
28.00, it will go parabolic.
Post Successful phase 1, and soon when
phase 2 AMD has begun, we will see
many days like today.
Really, when that first phase 2 AMD patient is
injected, six months later, Ocata's story will
be finishing act II.
PW_CC_12mar15(edited)
Our number one corporate objective for 2015 is the
initiation of the next phase of our clinical trials.
Act III, will be the build out of a tiny company
into something like the Apple of a new
healthcare system, a few years down wind.
It's the nature of technology. New technologies
cannot be stopped. Problems will arise, only
to be solved again, and again.
Nothing stops technology, not wars, not economic
crashes, not widespread ignorance. You can plot
the rise of any particular technology on a chart
over time.
Ocata is the BEGINNING of Stem Cell Technology.
Their first therapy is RPE tissue transplantation.
But it's the first of MANY to come.
RPE is the focal point right now. But behind this
point is an enormous Intellectual Property base
that provides a rock solid foundation.
Comments From the CC 12Mar2015
PW_CC_12mar15(edited)
Our number one corporate objective for 2015 is the initiation of the next phase of our clinical trials.
We plan to initiate our Phase II trial for dry AMD in the second quarter of this[2015] year.
This Phase II study will include up to three cohorts of approximately 20 patients each.
We intend to complete the first cohort dosing during 2015.
Each of the three cohorts will be treated with a different immune suppression regimen to determine how much, if any, immune suppression is required.
PW_CC_12mar15(end)
What,Huh? LOL 350 million dollars? for_Curing_Blindness
Did you remember to take out Ocata's current market
cap of 225 million?
That makes it only 125 million.
Over 20 years, when Human Embryonic Stem Cells
were first discovered, that's 6.25 a year, so what pilgrim?
Even if you start the clock at 2000, when the reverse
merger took place, and Two Moons KaCHING! was
transformed, thats about 8 1/3 mil a year.
What an Amazing Bargain For Curing Blindness!
Not to mention an entire suite of products, from the
underlying brand new field of technology,
and new branch of medicine.
It looks like the share price is holding steady in the
sixes. Ocata burns about $20 mil a year. If they
pull back, and batten down the hatches, and continue
with the first 20, phase 2 pivotal AMD patients, in
Q2, 2015, the data will take care of itself!
And Ocata has the money to do this already.
They have the doses already produced.
Phase 2 Data will bring money from all quarters,
all directions.
Comments From the CC 12Mar2015
PW_CC_12mar15(edited)
Our number one corporate objective for 2015 is the initiation of the next phase of our clinical trials.
We plan to initiate our Phase II trial for dry AMD in the second quarter of this[2015] year.
This Phase II study will include up to three cohorts of approximately 20 patients each.
We intend to complete the first cohort dosing during 2015.
Each of the three cohorts will be treated with a different immune suppression regimen to determine how much, if any, immune suppression is required.
PW_CC_12mar15(end)
Science is Provable, And Ocata is Science
This is something I find refreshing, not fearful.
It's beginning to look like if a person still has an
in tact eye structure, it can be repaired or rebuilt.
Ocata has completed an initial therapy for rebuilding
the retina's RPE layer, the retina's foundation.
And if this doesn't restore your sight, they are also
working on the photo-receptor cells as well, the rods
and cones.
The RPE layer is the foundation of the Retina, which is
the main sensor in your eye. If the RPE layer cannot be
made functional, you have stop right there with Ocata's
curative approach.
"There are ... dozens of retinal degenerative diseases and these diseases are ... caused by the loss of the RPE cells."
-Dr. Robert Lanza
Dr. Lanza
It would be nice to see the market
rally hard on one of these hit
articles.
I think one day with a 10 or 15% rally
would unwind quite a few shorts.
These article writers seem to fear nothing.
It's Utter Ignorance To Characterize Phase1_as_Tiny_and Insignificant!
It matters not what the motivation is for this characterization.
This characterization falls on its own, because it's wrong.
Ocata was founded in 1994, and human embryonic stem
cells were first isolated in 1998. If we begin the clock
from 1998, Ocata has, in less that two decades, invented
an entirely new technology based on hESCs discovered
in 1998.(link provided)
Phase 1/2 is NOW officially administered as of 31mar15,
yesterday.
And it's 38 patients large. Phase 1 trials are 20-80
people, as determined by the FDA. It's purposefully kept small
to minimize potential damage. (link provided)
All 38 patients are SAFE! And have either experienced a
halting of their disease or have experienced improvement.
And as time moves forward, this will become MORE refined,
not less. (link provided)
All safe !!! Two Moons KA-CHING, Indeed !!!
In Sunday's 60 Minutes program about the modified polio virus, cancer treatment, their phase 1, consisted of 22 patients, 11(eleven!) of them DIED! (link provided)
You can begin to grasp the sheer, utter, ignorance of the
characterization of Ocata's phase 1 as 'insignificant'.
Phase 1s are risky! The people participating deserve to
be appreciated. And the doctors and researchers too.
This is why Cathy's story is important. And why Cathy
is important, AND a hero! Thank you Cathy.(link provided)
This is a rude ignorance, of Ocata's brilliant success,
and achievement. No phase 1 trial is EVER insignificant.
Justice demands the record be set right.
Completing phase (1 combination 2) injections
is ANOTHER milestone.
We already knew it was working.-Lancet
Phase 1 is not the end.
It's a beautiful beginning.
Proof in the Lancet Article
(entire article in a downloadable pdf)
https://www.ocata.com/uploads/scientific_papers/2014-10-15-Schwartz-et-al%E2%80%93LANCET-2014.pdf
Human Embryonic Stem Cells wikipedia
In 1998, a breakthrough occurred when...James Thomson ...developed a technique to isolate and grow human embryonic stem cells in cell culture.
http://en.wikipedia.org/wiki/Embryonic_stem_cell
Phase 1 Guidelines FDA
http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=312.21
60 Minutes
http://www.cbsnews.com/videos/using-polio-to-kill-cancer-a-producers-notebook/
Cathy's Story
(The point is that it works, and heroic risk was taken)
(And her head didn't explode, she didn't die, it worked!)
Cathy: When I was younger I played a lot of competitive tennis, and I think when I was like in my later teens, I started playing a little more poorly. It was seeing the lines or the ball not quite as precisely, and calling the lines and stuff was a little more difficult. I woke up one morning and I looked across my room and I have a piece of furniture there, that's kind of this large armoire and it has a lot of carved detail on it, and I actually had my head to the side and I opened the operated eye and I looked at it, and for the first time I could see the detail in it, that I hadn't been able to see from the distance I was lying down. After that I just got up and I started looking at everything around the house, and looked at the grass, I mean looking at everything with one eye and then the other eye, because you know they only operated on the one eye, and I could see it a lot better than I had before, and I thought, wow, maybe there is something here that will really be working you know. It was pretty exciting.
(please, pretty please, somebody post Cathy's snippet to youtube)
We can, in the laboratory, take the stem cells and turn them into essentially brand new, young, juvenile retinal pigment epithelium and give somebody a fresh layer of these cells that could take them, if they have macular degeneration and say they're 40, 50, 70 years old, for the duration.
(for the duration means for the rest of their life)
Dr. Stephen Schwartz, UCLA and Jules Stein Institute
Charlie Rose show, 4/22/14
http://www.charlierose.com/watch/60378567
(It's not in lab any more, Jack !)
Just take a moment out of your dreary existence and
imagine if they were talking about brand new, young,
juvenile, SKIN cells !, and think for a moment how
many old ladies would want an 'injection' for the back
of their bony hands, or their saggy, gizzard necks.
This is all directly ahead, for Ocata, and all the old ladies.
Skin cells ARE epithelium.
And so are the lining of your blood vessels.
Supporting a successful completion of
Ocata's first, flagship product, their RPE therapy,
unlocks the entire panoply of Ocata's Intellectual
Property. I want to see this. And so should you.
answer from yahoo
Thanks to whoever piggybacked this to yahoo, and boiler for the answer!
No vasculization-OK
Is it still only 8 layers thick, and does this mean 8 cells, liver cells, thick?
thanks
btw I kinda started to hate Minger for his dismissile? of ONVO,
but maybe he was just rushed, heh.
Unless, of course, GE is the one behind the 16 million short position,
a hundred million dollars worth, of shorting behind the crushing of
ONVO.
I kinda hate whoever is behind this.
boilerupvic
Well technically he isn't wrong. I'll try to explain this in laymen terms. Most bioprinting uses a scaffolding or hydrogel approach. Organovo does drop cells into a dish, but they do it in specific patterns with incredible accuracy in X,Y and Z. When dropping different cells in conjunction with one another they naturally form specific shapes and sizes. This method (to my knowledge) most closely resembles human anatomy and tissue density. The trouble comes with building out a vascular network to increase the thickness of the tissue. This is a problem that literally everyone in bioprinting has.
There are multiple studies utilizing different angles to try to tackle this problem each showing promises in different areas. Some use hydro-gels, luckily for Onvo, they can also use hydro-gels when needed (it just isn't necessary for any of their commercial products at the moment or in the pipeline).
The important thing here is that currently no one has an answer for this problem. Organovo has products already in the pipeline that will generate revenue as they continue R&D. In addition to this, they have great scientific advisors, partnerships and collaboration with universities.
Dr. Stephen Minger comes off extremely dismissive and downplays a promising technology. It seemed like he was trying to hurry his talk along, but in the process failed to clarify why everyone is trying to work together to solve this problem. We don't know if/when will be able to print working vasculature, but we're making great progress and that's enough for me.
Are these True Comments about the liver
product Organovo produces?
This is from the 1:43:45 mark of the video
"Their liver construct is only 8 layers thick and
they can't get beyond that because they haven't
figured out how to vascularize."
"And they're actually not printing, they're dropping."
"Sorry, we've done a lot of competitor analysis."
Minger, Jan 2015
Okay buddy, I'll try not to hurt_dead_people's_feelings
in the future. Sorry.
The Captain's at_the_door_with_an_Axe_As_we_descend_towards_APRIL
Last year, 2014, April was quite an ornery girl. That was over a 50% plunge.
Two Moons Kachinas is_Now Two Moons KA-CHING !!!
Or it soon will be. Ever since the reverse split, last
August 27th, 2014, this stock has been rock steady
with only a few minor incursions below $6 dollars.
The two major spikes, at this reverse split, and
again at the historic NSDQ up listing,
look like EKG spikes of a heart beginning to beat !
Listen to Cathy AGAIN !
------------------------------
CATHY IS REAL !
------------------------------
RPE THERAPY IS REAL !
------------------------------
RPE THERAPY WORKS !
------------------------------
OCATA IS REAL !
------------------------------
KACHINA --- KA-CHING !
------------------------------
Cathy: When I was younger I played a lot of competitive tennis, and I think when I was like in my later teens, I started playing a little more poorly. It was seeing the lines or the ball not quite as precisely, and calling the lines and stuff was a little more difficult. I woke up one morning and I looked across my room and I have a piece of furniture there, that's kind of this large armoire and it has a lot of carved detail on it, and I actually had my head to the side and I opened the operated eye and I looked at it, and for the first time I could see the detail in it, that I hadn't been able to see from the distance I was lying down. After that I just got up and I started looking at everything around the house, and looked at the grass, I mean looking at everything with one eye and then the other eye, because you know they only operated on the one eye, and I could see it a lot better than I had before, and I thought, wow, maybe there is something here that will really be working you know. It was pretty exciting.
(please somebody post Cathy's snippet to youtube)
We can, in the laboratory, take the stem cells and turn them into essentially brand new, young, juvenile retinal pigment epithelium and give somebody a fresh layer of these cells that could take them, if they have macular degeneration and say they're 40, 50, 70 years old, for the duration.
(for the duration means for the rest of their life)
Dr. Stephen Schwartz, UCLA and Jules Stein Institute
Charlie Rose show, 4/22/14
http://www.charlierose.com/watch/60378567
I'd like a fresh layer of RPE cells please, thank you very much.
Thank you Bob Lanza !
Here's a video for Gene Therapy for the RPE65 gene.
It's also NOT a drug, also going through FDA Phase 1,2,3
Walmart Could Crush Amazon, if_it_Bought_Some_Vans_and_Hired_Some_TeenAgers
So why doesn't Walmart Do it?
Because they're all in on it.
We're meat robots to these 'elite' people.
They suck us all dry, because they're rich, lazy and not very moral.
Amazon is based on delivery, and that's it.
Free delivery, from Lowes, Home Depot, Grocery Chains,
would pulverize the distortion that is Amazon.
Books Okay, I'll give them that.